The identification of human leukocyte antigen-G (HLA-G) as a key factor in this process suggests that targeted therapies aimed at disrupting the sEV-mediated delivery of HLA-G may hold promise for enhancing the effectiveness of anti-tumor immune responses in the context of RCC (30). This evidence concerns the gene HLA-G and neoplasm.